摘要
目的多发性骨髓瘤(MM)是来源于B淋巴细胞的恶性肿瘤,以终末分化的浆细胞的克隆性增生为显著特征。骨质破坏是其突出的临床特点之一,与疾病的预后直接相关。多种细胞因子参与了骨质破坏的过程。加强对MM骨病机制的研究将为临床靶向治疗和改善患者生存质量提供更好的依据。本研究旨在探讨神经元特异性烯醇化酶(NSE)在骨髓瘤骨病中的作用。方法采用ELISA和实时荧光定量RT-PCR方法,对MM患者血浆和骨髓中以及骨髓瘤细胞株U266中NSE水平进行定量分析,初步分析其在骨髓微环境中的表达情况,了解其与MM骨病的关系。结果U266和67%的患者中NSE水平明显高于对照组(P<0.01),且随着临床分期和骨质破坏程度的增加,NSE表达总体呈上升趋势。结论 U266和大部分骨髓瘤骨病患者中NSE表达水平增高,且与MM骨病程度和疾病分期相关,提示NSE可能在骨髓瘤骨病中起重要作用。
Objective Multiple myeloma(MM) was characterized by cloning proliferation of terminally differentiated plasma ceils. The bone destruction,which serves as a predominant clinical feature of MM patients, was closely related to prognosis. A se- ries of cytokines had been proved to work in myeloma bone disease. To explore the mechanism of MBD would be helpful for effec- tive targeted therapies and improving life quality of MM patients. In order to explore the role of neuron specific enolase(NSE) in myeloma bone disease(MBD). Methods ELISA and real-time PCR was used to quantitate the NSE in multiple myeloma and MM cell line( U266 ). Based on the data, the levels in bone marrow microenvironment and the associations between myeloma bone disease and myeloma cells were analyzed. Results The results showed that U266 and about 67% patients with multiple myeloma had increased levels and copies. A significantly larger proportion of MM patients had increased levels of NSE compared to the con- trol ( P 〈 0.01 ), NSE levels increased progressively according to the bone damage degree and clinical stages. Conclusion U266 and most of patients with MBD had increased levels of NSE. The up regulation of NSE may contribute to myeloma bone disease and stages, indicating that it was probably another critical cytokine which triggers bone damage.
出处
《中华全科医学》
2012年第3期337-338,F0003,共3页
Chinese Journal of General Practice
基金
2007年云南省科技厅教育厅联合专项(2007C0037R)